- Home
- NMRA vs RCS Comparison
NMRA vs RCS Comparison
Compare NMRA & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- RCS
- Stock Information
- Founded
- NMRA 2019
- RCS 1994
- Country
- NMRA United States
- RCS United States
- Employees
- NMRA N/A
- RCS N/A
- Industry
- NMRA
- RCS Investment Managers
- Sector
- NMRA
- RCS Finance
- Exchange
- NMRA Nasdaq
- RCS Nasdaq
- Market Cap
- NMRA 291.5M
- RCS 358.4M
- IPO Year
- NMRA 2023
- RCS N/A
- Fundamental
- Price
- NMRA $1.71
- RCS $7.01
- Analyst Decision
- NMRA Hold
- RCS
- Analyst Count
- NMRA 8
- RCS 0
- Target Price
- NMRA $5.83
- RCS N/A
- AVG Volume (30 Days)
- NMRA 470.3K
- RCS 141.1K
- Earning Date
- NMRA 11-11-2025
- RCS 01-01-0001
- Dividend Yield
- NMRA N/A
- RCS 10.12%
- EPS Growth
- NMRA N/A
- RCS N/A
- EPS
- NMRA N/A
- RCS N/A
- Revenue
- NMRA N/A
- RCS N/A
- Revenue This Year
- NMRA N/A
- RCS N/A
- Revenue Next Year
- NMRA N/A
- RCS N/A
- P/E Ratio
- NMRA N/A
- RCS N/A
- Revenue Growth
- NMRA N/A
- RCS N/A
- 52 Week Low
- NMRA $0.61
- RCS $4.51
- 52 Week High
- NMRA $14.09
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- NMRA 45.77
- RCS 31.64
- Support Level
- NMRA $1.74
- RCS $7.53
- Resistance Level
- NMRA $1.85
- RCS $7.41
- Average True Range (ATR)
- NMRA 0.11
- RCS 0.21
- MACD
- NMRA -0.02
- RCS -0.09
- Stochastic Oscillator
- NMRA 10.14
- RCS 1.06
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.